Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Head and Neck Neoplasms 4Hot Flashes 3Breast Neoplasms 3Pain 2Vomiting 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Neurotoxicity Syndromes 1Neuralgia 1Neoplasms 1Nausea 1Mucositis 1Lung Neoplasms 1Abnormalities, Radiation-Induced 1

Interventions

Oxaliplatin 4Sodium Chloride 3Paclitaxel 3Carboplatin 3xaliproden 2Taxes 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Magnesium Sulfate 2Leucovorin 2Fluorouracil 2Calcium Gluconate 2neurotropin 1glutamic acid diethyl ester 1Vitamin E 1Thioctic Acid 1Temozolomide 1Saline Solution 1Radiosurgery 1Prednisolone 1Methylprednisolone 1Memantine 1Lamotrigine 1Ketamine 1Glutathione 1Glutamic Acid 1Ginkgo Extract 1Gabapentin 1Duloxetine Hydrochloride 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neurotoxicity Syndromes × Gabapentin × Clear all
NCT00027963 2016-07-04

Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy

Alliance for Clinical Trials in Oncology

Phase 3 Completed
100 enrolled

Pain, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡